

Endocrine Abstracts

May 2018 Volume 56
ISSN 1479-6848 (online)

20th European Congress of
Endocrinology 2018

19–22 May 2018, Barcelona, Spain



published by
bioscientifica

Online version available at
www.endocrine-abstracts.org



20th European Congress of Endocrinology 19–22 May 2018

EDITORS

The abstracts were marked by the Abstract marking Panel selected by the programme Organising Committee

Programme Organising Committee

Márta Korbonits (UK) Chair
Barbara Obermayer-Pietsch (Austria) Co-chair
Raúl M. Luque (Spain) Co-chair
Manel Puig Domingo (Spain) LOC chair
Anders Sundin (Sweden)
Andrea Isidori (Italy)
Camilla Schalin-Jääntti (Finland)
Carlo Acerini (UK)
Cesar Luiz Boguszewski (Brazil)

Claudio Marcocci (Italy)
Cynthia Andoniadou (UK)
Darko Kastelan (Croatia)
Djuro Macut (Serbia)
Gérald Raverot (France)
Guillaume Assié (France)
Jens Otto Lunde Jørgensen (Denmark)
Josef Köhrle (Germany)
Ljiljana Marina (Serbia)

Manuel Tena-Sempere (Spain)
Marek Niedziela (Poland)
Maria Alevizaki (Greece)
Endre Nagy (Hungary)
John Kopchick (USA)
Sebastian Neggers (The Netherlands)
Simona Glasberg (Israel)
Susan Webb (Spain)

Local Organising Committee

Manuel Puig Domingo (Spain) LOC chair
Javier Salvador (Pamplona)
Felipe Casanueva (Santiago de Compostela)
Juan Bernal (Madrid)
Antonio Picó (Alicante)
Mónica Marazuela (Madrid)
Pilar Santisteban (Madrid)

Alfonso Soto (Sevilla)
Francisco Tinahones (Málaga)
Mercedes Robledo (Madrid)
Sonia Gaztambide (Bilbao)
Mar Malagón (Córdoba)
Carlos Diéguez (Santiago de Compostela)
Wifredo Ricart (Girona)

Didac Mauricio (Barcelona)
Josep Vidal (Barcelona)
Jordi Mesa (Barcelona)
Albert Goday (Barcelona)
Manuel Pérez Maraver (Barcelona)
Joan Vendrell (Tarragona)
Albert Lecube (Lleida)

Abstract Marking Panel

C Acerini UK	C Follin Sweden	C Luiz Boguszewski Brazil	M Ruchala Poland
M Alevizaki Greece	S Franks UK	R M Luque Spain	E Rutten Belgium
N Alonso	W Fraser UK	M Luster Germany	P Saunders UK
C Alvarez	J Frystyk Denmark	D Macut Serbia	S Schmid Germany
C Andoniadou	L Fugazzolla Italy	A Maggi Italy	P Schöffski Belgium
W Arlt UK	F Gabalec Czech Republic	M Maggi Italy	J Schopohl Germany
G Assié France	F Giorgino Italy	M Mannelli Italy	R Semple UK
S Babajko France	N Glynn	F Mantero Italy	M Simoni Italy
K Badenhoop Germany	J Gomez-Ambrosi Spain	JP Martinez-Barbera	U Smith Sweden
P Beck-Peccoz Italy	R Granata Italy	L Masmiquel	A Spada
J Bertherat France	J Gromoll Germany	G Mastorakos Greece	G Stalla Germany
F Beuschlein Germany	A Grossman UK	D Mauricio	C Stratakis USA
C Bevan UK	R Hampl Czech republic	C McCabe UK	T Tankova Bulgaria
H Biebermann Germany	M Heikinheimo Finland	R Mitchell UK	M Tena-Sempere
K Boelaert UK	A Hoellich Germany	J Mittag	M Terzolo
h Boelen The Netherlands	W Hogler UK	L Morin-Papunen Finland	M Theodoropoulou Germany
G Brabant Germany	I Huhtaniemi UK	N Morton UK	C Thompson Ireland
M L Brandi Italy	E Husebye	A Mukherjee UK	P Thompson UK
K Briot France	P Igaz Hungary	E Nagy Hungary	V Tillmann Estonia
M Brown UK	I Illovayskaya Russia	J Newell-Price UK	M Toth Hungary
C Buchanan UK	T Isailovic	B Obermayer-Pietsch Austria	S Tsagarakis Greece
P Burman Sweden	E R Isenovic Serbia	P Oliveira Portugal	A Tsapas Greece/UK
S Cannavo Italy	M-L Jaffrain-Rea Italy	U Pagotto Italy	M Tzanela Greece
J Cap Czech Republic	B Jarzab Poland	S Papopolous Netherlands	E Valassi Spain
J S Carroll UK	D Jezova Slovakia	R Peeters The Netherlands	E van den Akker Netherlands
J Castano Spain	M Jorda	L Persani Italy	A van der Klaauw UK
P Chanson France	A Kalsbeek Netherlands	M Pfeifer Slovenia	A J van der Lelij Netherlands
F Chiarelli Italy	G Kalsas Greece	P Pilgler Germany	J van Eck The Netherlands
I Chiodini Italy	A Karlsson Sweden	V Pirags Latvia	W van Hul Belgium
J Chowen Spain	M Keil USA	M Poutanen Finland	L van Rossum Netherlands
T Coll UK	F Kelestimur Turkey	D Power Portugal	B Verges France
C Daousi UK	R Kineman USA	V Prevot France	J Visser The Netherlands
M Dattani UK	M Korbonits UK	M Puig Domingo Spain	P Vitti Italy
C Dayan UK	B Kos-Kudla Poland	S Radian UK	V Volke Estonia
W de Herder Netherlands	N Krone UK	N Rahman Finland	R Voutilainen Finland
W Dhillon UK	M Krsek Czech Rep	B Rainey USA	I Wilkinson UK
G Di Dalmazi Germany	H Krude Germany	E Rajpert-De Meyts Denmark	G Williams UK
J Drouin Canada	M Laan Germany	G Raverot France	Z Wu Germany
L Duntas Greece	P Lakatos Hungary	M Reincke Germany	P Yeoh UK
S Duran	E Lalli	J Reverter	B Yildiz Turkey
G Eisenhofer Germany	J Laven The Netherlands	S Rice UK	J Young France
F Fallo	G Lavery UK	G Riesco-Izaguirre	C Zafon
M Fassnacht Germany	T Links The Netherlands	M Robledo Spain	M Zatzelli Italy
R Feelders The Netherlands	P Lips Netherlands	P Rodien France	H Lehnert Germany
U Feldt-Rasmussen Denmark	S Llahana UK	H Romijn The Netherlands	
F Flamant France	M Lopez Spain	C Ronchi Italy	
E Fliers The Netherlands	A Luger Austria	G P Rossi	

The ESE would like to thank its Corporate Members and the ECE 2018 sponsors

ECE Corporate Members
Premium Corporate Members

Ipsen
Pfizer
Shire Services BVBA

Corporate Members

Laboratoire HRA Pharma
Novartis Pharmaceuticals
Novo Nordisk
Otsuka Pharmaceuticals Europe Ltd
Sandoz International GmbH
Siemens-Healthineers
Strongbridge Biopharma

Gold Sponsors

Ipsen
Pfizer
Novartis Pharmaceuticals



ESE Office
Euro House
22 Apex Court
Woodlands
Bradley Stoke
Bristol BS32 4JT, UK

Contact: Andrea Davis
Tel: +44 (0)1454 642247
Fax: +44 (0)1454 642222
E-mail: info@euro-endo.org
Web site: www.es-hormones.org



ECE 2016 Secretariat
Bioscientifica Ltd
Euro House, 22 Apex Court
Woodlands
Bradley Stoke
Bristol BS32 4JT, UK

Contact: Niki Cripps
Tel: +44 (0)1454 640467
Fax: +44 (0)1454 642222
E-mail: ece2016@bioscientifica.com
Website: <http://www.bioscientifica.com>

CONTENTS

20th European Congress of Endocrinology 2018

PRIZE LECTURES AND BIOGRAPHICAL NOTES

The European Journal of Endocrinology Prize Lecture	EJE1
The Geoffrey Harris Prize Lecture	GH1
European Hormone Medal Lecture	EHM1
Clinical Endocrinology Trust Lecture	CET1

PLENARY LECTURES

Contraception: Past and future	PL1
Bone regulates the Brain	PL2
The wonder world of GnRH neurons	PL3
The Retina as a Window for Exploring the Brain in Diabetes	PL4
The link between insulin and fatty liver	PL5
Does therapy for thyroid dysfunction decrease mortality?	PL6
Metabolic control of longevity	PL7

SYMPOSIA

Predicting events in autoimmune thyroid disease	S1.1–S1.3
Salt & Sweet	S2.1–S2.3
Bile Acid & Microbiota (<i>Endorsed by Endocrine Connections</i>)	S3.1–S3.3
Environmental effects on endocrine functions	S4.1–S4.3
The role of sperm epigenome in fertility and inheritance	S5.1–S5.3
Precision Medicine for diabetes (<i>Endorsed by the European Journal of Endocrinology</i>)	S6.1–S6.3
Expanding the spectrum of thyroid hormone use (<i>Endorsed by the European Journal of Endocrinology</i>)	S7.1–S7.3
Bone fragility – from bench to clinic	S8.1–S8.3
EAA /ESE Session: Male gonadal function versus general health and vice versa	S9.1–S9.3
Hot topics in NETs	S10.1–S10.3
Novel aspects of Craniopharyngioma	S11.1–S11.3
Why do fractures occur in endocrine disorders, and how should they be handled?	S12.1–S12.3
The colours of fat	S13.1–S13.3
Neuroendocrine basis of reproductive disorders	S14.1–S14.3
EYES: New aspects in the study of neuroendocrine diseases	S15.1–S15.6
Changing practice in the management of thyroid neoplasms	S16.1–S16.3
Recent advances in Primary Adrenal Macronodular Hyperplasia	S17.1–S17.3
Borderline testosterone and metabolic outcomes among sexes: clinical relevance	S18.1–S18.3
New Aspects of Pituitary Regulation	S19.1–S19.3
All you need to know about lipodystrophy (<i>Endorsed by Endocrine Connections</i>)	S20.1–S20.3
The Dance of Adrenal and Gonads (<i>Endorsed by Endocrine Connections</i>)	S21.1–S21.3
The fatty bone	S22.1–S22.3
Pre-diabetes	S23.1–S23.3
Ups and downs of hypothalamo-pituitary hormones	S24.1–S24.3
Late Breaking	S25.1–S25.3
Cortisol: Too much of a Good Thing	S26.1–S26.3
Emerging treatments in osteoporosis	S27.1–S27.3
Endocrinology Meets Immunology	S28.1–S28.3
Thyroid hormone action: regulation and clinical implications	S29.1–S29.3
Disorders of Sexual Development (DSD)	S30.1–S30.3
Special Symposium: Bone & Vitamin D (<i>Endorsed by Endocrine Connections</i>)	SS1.1–SS1.3
Guidelines: ESE - ENSAT guidelines on the management of adrenocortical carcinoma in adults	GL1.1–GL1.6
Endo-ERN: concrete examples of added value for patient care	ERN1.1–ERN1.3

NEW SCIENTIFIC APPROACHES NSA1–NSA6

DEBATES

Adrenal venous sampling vs. imaging for primary aldosteronism: beware of the caveats!
(Endorsed by the European Journal of Endocrinology) D1.1–D1.2

Receptor profiling is useful for predicting pituitary therapy *(Endorsed by the European Journal of Endocrinology)* D2.1–D2.2

Subclinical hypothyroidism is a disease D3.1–D3.2

AMH as the Primary Marker for Fertility D4.1–D4.2

Pregnant women should be screened for thyroid hormones and antibodies D5.1–D5.2

Endocrine disruptors: Regulatory vs. Scientific Perspectives *(Endorsed by Endocrine Connections)* D6.1–D6.2

MEET THE EXPERT SESSIONS

. MTE1–MTE16

. MTBS1–MTBS3

NURSE SESSIONS

. N1.1–N1.3

. N2.1–N2.4

. N3.1

. N4.1–N4.5

ORAL COMMUNICATIONS

Benign thyroid diseases OC1.1–OC1.5

Look who is controlling your gonads! OC2.1–OC2.5

New insights in bone disorders OC3.1–OC3.5

Novel insights into prediabetes and type 2 diabetes OC4.1–OC4.5

Diving deep into adrenal cortex diseases OC5.1–OC5.5

Genetic and environmental determinants of obesity and insulin resistance OC6.1–OC6.5

Genomic and clinical aspects of endocrine tumours OC7.1–OC7.5

MicroRNAs as biomarkers in endocrine diseases OC8.1–OC8.5

Thyroid from basics to clinics OC9.1–OC9.5

Cardiovascular aspects of endocrine diseases OC10.1–OC10.5

Clinical practice in endocrine tumours: combining conventional and molecular features OC11.1–OC11.5

Novel aspects of puberty development and Cushing’s disease OC12.1–OC12.5

The curious case of growth hormone OC13.1–OC13.5

What is new in gestational and type 1 diabetes? OC14.1–OC14.5

GUIDED POSTERS

Acromegaly GP2–GP12

Adrenal Case reports GP13–GP21

Adrenal clinical GP22–GP31

Adrenal cortex GP32–GP41

Adrenal medulla and NETs GP42–GP52

Bone and Osteoporosis GP53–GP62

Cardiovascular GP63–GP70

Diabetes Complications GP71–GP81

Diabetes Epidemiology GP82–GP92

Diabetes Therapy GP93–GP104

Diabetes Translational GP105–GP116

Endocrine Case Reports GP117–GP126

Female Reproduction GP127–GP137

Neuroendocrinology GP138–GP148

Obesity GP149–GP161

Paediatrics, Developmental & Female Reproduction GP162–GP171

Parathyroid GP172–GP183

Pituitary / Growth Hormone & IGF Axis GP184–GP193

Pituitary Basic GP194–GP201

Pituitary Clinical	GP202–GP213
Reproduction	GP214–GP223
Thyroid Cancer - Diagnostics & Treatments	GP224–GP235
Thyroid Cancer - Translational	GP236–GP245
Thyroid non cancer	GP246–GP254
Thyroid non cancer - Autoimmune Thyroid disease/pregnancy	GP255–GP264
Thyroid non cancer - Benign Thyroid disease/treatment	GP265–GP274

POSTER PRESENTATIONS: ADRENAL AND NEUROENDOCRINE TUMOURS

Adrenal cortex (to include Cushing's)	P1–P70
Adrenal medulla	P71–P81
Calcium & Vitamin D metabolism	P82
Cardiovascular Endocrinology and Lipid Metabolism	P83–P85
Clinical case reports - Pituitary/Adrenal	P86–P106
Clinical case reports - Thyroid/Others	P107–P109
Endocrine tumours and neoplasia	P110–P143
Female Reproduction	P144
Neuroendocrinology	P145–P154
Obesity	P155
Paediatric endocrinology	P156
Pituitary - Basic	P157–P159
Steroid metabolism + action	P160–P161
Thyroid (non cancer)	P162
Thyroid cancer	P163

POSTER PRESENTATIONS: CALCIUM AND BONE

Bone & Osteoporosis	P164–P201
Calcium & Vitamin D metabolism	P202–P260
Cardiovascular Endocrinology and Lipid Metabolism	P261
Clinical case reports–Pituitary/Adrenal	P262
Clinical case reports - Thyroid/Others	P263–P274
Endocrine Disruptors	P275
Endocrine Nursing	P276
Endocrine tumours and neoplasia	P277–P279
Female Reproduction	P280

POSTER PRESENTATIONS: DIABETES, OBESITY AND METABOLISM

Adrenal cortex (to include Cushing's)	P281
Bone & Osteoporosis	P282–P288
Calcium & Vitamin D metabolism	P289–P291
Cardiovascular Endocrinology and Lipid Metabolism	P292–P316
Clinical case reports - Thyroid/Others	P317–P328
Developmental endocrinology	P329–P330
Diabetes (to include epidemiology, pathophysiology)	P331–P403
Diabetes complications	P404–P475
Diabetes therapy	P476–P518
Endocrine Disruptors	P519–P523
Endocrine Nursing	P524
Female Reproduction	P525
Neuroendocrinology	P526
Nuclear receptors and Signal transduction	P527–P529
Obesity	P530–P607
Paediatric endocrinology	P608–P610
Steroid metabolism + action	P611
Thyroid cancer	P612

POSTER PRESENTATIONS: ENVIRONMENT, SOCIETY AND GOVERNANCE

Diabetes therapy	P613
Endocrine Disruptors	P614–P615
Neuroendocrinology	P616
Pituitary - Clinical	P617
Thyroid (non-cancer)	P618–P620

POSTER PRESENTATIONS: INTERDISCIPLINARY ENDOCRINOLOGY

Adrenal cortex (to include Cushing's)	P621–P622
Calcium & Vitamin D metabolism	P623
Cardiovascular Endocrinology and Lipid Metabolism	P624–P629
Clinical case reports - Pituitary/Adrenal	P630–P631
Clinical case reports - Thyroid/Others	P632–P636
Developmental endocrinology	P637
Diabetes (to include epidemiology, pathophysiology)	P638–P642
Endocrine Disruptors	P643–P645
Endocrine tumours and neoplasia	P646–P656
Female Reproduction	P657–P662
Growth hormone IGF axis - basic	P663–P665
Neuroendocrinology	P666–P672
Nuclear receptors and Signal transduction	P673–P675
Obesity	P676
Paediatric endocrinology	P677–P679
Steroid metabolism + action	P680–P682
Thyroid (non-cancer)	P683–P684
Thyroid cancer	P685

POSTER PRESENTATIONS: PITUITARY AND NEUROENDOCRINOLOGY

Adrenal cortex (to include Cushing's)	P686–P689
Clinical case reports - Pituitary/Adrenal	P690–P727
Developmental endocrinology	P728
Endocrine Nursing	P729
Endocrine tumours and neoplasia	P730–P736
Female Reproduction	P737–P738
Growth hormone IGF axis - basic	P739–P742
Neuroendocrinology	P743–P770
Paediatric endocrinology	P771–P775
Pituitary - Basic	P776–P787
Pituitary - Clinical	P788–P888

POSTER PRESENTATIONS: REPRODUCTIVE ENDOCRINOLOGY

Adrenal cortex (to include Cushing's)	P889
Bone & Osteoporosis	P890
Cardiovascular Endocrinology and Lipid Metabolism	P891–P892
Clinical case reports - Thyroid/Others	P893–P898
Developmental endocrinology	P899–P901
Diabetes (to include epidemiology, pathophysiology)	P902
Endocrine Disruptors	P903–P907
Endocrine Nursing	P908–P909
Endocrine tumours and neoplasia	P910
Female Reproduction	P911–P958
Male Reproduction	P959–P975
Neuroendocrinology	P976
Paediatric endocrinology	P977–P979
Pituitary - Basic	P980

Steroid metabolism + action	P981–P983
Thyroid (non-cancer)	P984

POSTER PRESENTATIONS: THYROID

Clinical case reports - Thyroid/Others	P985–P1005
Developmental endocrinology	P1006
Endocrine Disruptors	P1007–P1008
Endocrine tumours and neoplasia	P1009–P1010
Nuclear receptors and signal transduction	P1011
Paediatric endocrinology	P1012
Thyroid (non-cancer)	P1013–P1117
Thyroid cancer	P1118–P1205

ePOSTER PRESENTATIONS

Adrenal and Neuroendocrine Tumours	EP1–EP28
Calcium and Bone	EP29–EP34
Diabetes, Obesity and Metabolism	EP35–EP90
Environment, Society and Governance	EP91
Interdisciplinary endocrinology	EP92–EP99
Pituitary and Neuroendocrinology	EP100–EP135
Reproductive Endocrinology	EP136–EP154
Thyroid	EP155–EP191

INDEX OF AUTHORS

regulates expression of various genes that mediate cellular response to xenobiotics. The exact functional role of two AHR single nucleotide polymorphisms (SNPs); Arginine554Lysine (Arg554Lys) and Valine570Isoleucine (Val570Ile) has not yet been established, however studies suggest that these mutations might increase risk of developing PAs. To date, functional analysis of regarding the significance of these AHR SNPs in pituitary pathophysiology has never been analysed.

Aims

- Elucidate the effect of wildtype and polymorphic AHR on GH3 cell proliferation and on AHR-transcriptional response in the presence and absence of TCDD.
- Determine the allele frequency of the most common AHR SNP; the Arg554Lys in PA patients and in a small cohort of the Maltese population.

Method

The two missense mutations were introduced within the AHR-expressing vector and transfected in GH3 cells by magnetofection, followed by the exposure to TCDD. Cell viability of GH3 transfected cells was measured using the MTT assay. Functional analysis of GH3 transfected cells treated with TCDD was carried out using luciferase assay and real-time PCR to detect and quantify the AHR-transcriptional activity. Genotyping of the Arg554Lys was performed on PA patients and neonatal controls using allele specific PCR. The Mann-Whitney test was used to compare two groups and Kruskal-Wallis test was used to compare three groups or more.

Results

In the absence and presence of low TCDD concentrations (1 and 10 nM), over-expression of wildtype AHR (wtAHR) did not affect GH3 cell proliferation. GH3 cells transfected with the AHR mutants did not exhibit any significant differences in their proliferative ability when compared with the wtAHR, both in the presence and absence of TCDD. Luciferase reporter analysis showed that there was a significant difference between the treated and untreated wtAHR ($P=0.016$), however this difference was not observed between the treated and untreated AHR mutants. Statistically significant difference in *Cyp11a1* gene expression analysis was detected between the treated and untreated wtAHR ($P=0.021$), Arg554Lys ($P=0.005$) and Val570Ile ($P=0.054$). Genotyping of the Arg554Lys in patients with PA gave a minor allele frequency (MAF) of 3% vs 0% in neonatal controls.

Conclusion

Gene expression and quantification analyses of AHR-target genes suggests that these AHR mutants might interfere with AHR target gene expression. Genotyping results suggested that this mutation is quite rare and may be similar to the frequencies of other European populations.

DOI: 10.1530/endoabs.56.P777

P778

Comparative differential effects of secretagogues upon regulation of pituitary GH in several vertebrates

Valeria Alejandra Urban Sosa¹, José Ávila Mendoza², Martha Carranza Salas¹, Carlos Guillermo Martínez Moreno¹, Maricela Luna Muñoz¹ & Carlos Arámburo¹

¹Universidad Nacional Autónoma de México, Instituto de Neurobiología, Querétaro, Mexico; ²University of Michigan, Ann Arbor, USA.

It is known that the synthesis and release of pituitary GH is controlled by complex neuroendocrine mechanisms that involve several neuropeptides, such as GHRH, SST, PACAP, TRH, GnRH, Ghrelin, among other regulators. Previous reports indicate that, during vertebrate evolution, the potency and efficacy of these secretagogues may vary and play differential effects upon GH regulation. In this work we aimed to study, *in vitro*, the capacity of these peptides to control the expression and secretion of pituitary GH in three vertebrate models: rat (mammals), chicken (birds) and iguana (reptiles), employing pituitary cultures at different incubation periods (0–6 h) and two doses of the secretagogues (1 and 10 nM). Results showed that GHRH significantly stimulated GH mRNA expression as well as GH secretion in the three species within the first hour of incubation, in comparison to the controls. However, its effect upon GH mRNA was 60 times greater in iguana than in the other species. TRH had no effect on GH secretion in any incubation period, but it stimulated GH mRNA expression in all species and, in the case of iguana, its effect was 150 times higher than in the others. PACAP stimulated GH mRNA expression at 4 h in chicken pituitary cultures, whereas no significant differences were observed in rats and iguanas.

Ghrelin increased GH secretion in chickens, but had no effect in its mRNA synthesis, contrary to what was found in iguana cultures where GH mRNA significantly diminished. GnRH stimulated both GH mRNA expression and GH release in chicken pituitary cultures, while in iguana only GH secretion was significantly increased. On the other hand, SST strongly inhibited GH mRNA expression and GH release in the iguana, while no significant effect was directly observed in rats and chickens, at the doses and time-frame conditions employed. Results indicate that there is a differential effect of these secretagogues upon GH synthesis and secretion during vertebrate evolution, and further studies are needed to understand how these mechanisms have evolved.

DOI: 10.1530/endoabs.56.P778

P779

Next generation sequencing for characterization of mitochondrial genome in pituitary adenomas

Kinga Németh¹, Ottó Darvasi², István Likó², Nikolette Szűcs¹, Sándor Czirják³, Lilla Reiniger⁴, Borbála Szabó⁵, Péter Igaz¹, Attila Patócs^{2,5} & Henriett Butz^{2,5}

¹2nd Department of Medicine, Faculty of Medicine, Semmelweis University, Budapest, Hungary; ²MTA-SE 'Lendület' Hereditary Endocrine Tumors Research Group, Hungarian Academy of Sciences and Semmelweis University, Budapest, Hungary; ³National Institute of Clinical Neurosciences, Budapest, Hungary; ⁴1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary; ⁵Department of Laboratory Medicine, Semmelweis University, Budapest, Hungary.

Introduction

Disrupted mitochondrial functions and genetic variations of mitochondrial DNA (mtDNA) have been observed in different tumors. Regarding pituitary adenomas mtDNA was evaluated only in oncocytic type using PCR based methods and it showed high prevalence of Complex I variants. Next generation sequencing (NGS) allows high throughput sequencing and it is useful for accurate identification of heteroplasmy of mitochondrial genome as well.

Aim

We aimed to investigate the entire mitochondrial genome in different adenoma types.

Material and methods

We collected 22 gonadotroph (GO), 11 GH producing (GH) and 11 null-cell (NC) adenoma specimens from samples removed by transsphenoidal surgery. From fresh frozen tissues DNA extraction was performed using QIAamp Fast DNA Tissue Kit. For library preparation VariantPro Amplicon Mitochondrion Panel kit was used. The total mtDNA (16569 bp) was sequenced on Illumina MiSeq Instrument. Following complex bioinformatic analysis Revised Cambridge Reference Sequence (rCRS) of the human mitochondrial DNA was used as reference. Heteroplasmy was determined using 3% cutoff.

Results

The whole mitochondrial genome were covered by 630 ± 370 (avg \pm s.e.) reads per base. 496 variants were identified in adenomas compared to reference sequence. Overall a low (7.22%) heteroplasmy prevalence was found. Based on mitochondrial sequence variants by hierarchical cluster analysis we could not discriminate different adenoma types. No association between Ki-67 index or recurrent-nonrecurrent status of adenomas and mitochondrial variants were detected. Four variants appeared more often in null-cell adenomas compared to gonadotroph adenomas (chrM_188: 18% vs 0%, chrM_16093: 18% vs 0%, chrM_185: 27% vs 0% and chrM_14798: 36% vs 5%; Padj=0.0246, 0.0246, 0.01542 and 0.01829, respectively). Of these variants chrM_14798, chrM_4216 and chrM_15452 are non-synonymous polymorphisms leading to amino acid change in MT-CYB (mitochondrially encoded cytochrome b) and in MT-ND1 (mitochondrially encoded NADH dehydrogenase 1) genes. We identified chrM_16189 variant (non-protein coding variant) in 40% (6/15) of nonrecurrent adenomas compared to recurrent ones where this variant was not present (0/11) ($P=0.0209$).

Conclusions

Next-generation sequencing is a reliable method for investigating mitochondrial genome and heteroplasmy in pituitary adenomas. In pituitary adenomas the prevalence of heteroplasmy of mitochondrial genome is low suggesting that these alterations may not influence mitochondrial function considerably. Of pituitary

tumours only null cell adenomas possess alterations of mitochondrial genome with potential functional consequences suggesting that during the development of this subtype of pituitary tumours mitochondrial function-associated mechanisms may have role.

DOI: 10.1530/endoabs.56.P779

P780

Pituitary cell activation and recruitment in hypothyroidism

Fernando Oroz, Montserrat García-Layandeira, Sihara Pérez-Romero, Ángela García-Rendueles & Clara V Álvarez
Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), Santiago de Compostela, Spain.

Pituitary stem cells have been characterized in the postnatal pituitary. We now know they are organized in a niche and co-express specific markers such as Sox2, Sox9 or Gfra2. Although many studies by our group and others have been dedicated to its characterization *in situ* it is under discussion their role in the maintenance and turnover of the pituitary in physiological conditions or physiological pituitary challenges. It's not known if the stem cells are required and which molecular mechanisms are implicated in recruitment/differentiation. We established a model of hypothyroidism in rodents similar to human conditions in which levels of thyroxine are maintained just below the lower normal cut-off. We studied pituitary extracts in a precise time-course for stem cell and differentiation markers of thyrotropes. We have found that Shh is increased immediately after the establishing of the hypothyroidism. Following this, we purified the Gfra2+ stem cell population from vehicle and short-term hypothyroid animals and grown them as spheres in absence of serum. Spheres grow during the days of culture duplicating from day 1 to day 5 when they reach a plateau. Gfra2+ cells obtained from hypothyroid animals produce a significantly higher level of spheres per well both at day 1 and at day 5. When cultured in presence of cyclopamine, a Shh inhibitor, the number of spheres is significantly reduced in the hypothyroid Gfra2+ but not in the control wells. We used immunofluorescence techniques to see what happen in the intact pituitary niche *in vivo*. A genetic mouse model of tracing where Gfra2/Sox2 positive cells are induced to express GFP long-term after the tamoxifen injection was followed in a time-course under the same conditions of above vehicle/hypothyroidism. There was a significant increase of the Sox2 positive cell in long-term hypothyroid mice compared with vehicle treated. Tracing the GFP+ population through a time-course, we detected a significant increase in the double GFP/TSH+ cells in the adenopituitary of hypothyroid mice compared to vehicle treated. This data confirm that Sox2 positive cells recruited from the pituitary niche are able to differentiate into TSH producing cells. In summary, our results indicate that the Gfra2/Sox2 population, the pituitary stem cells, are activated when a mild hypothyroidism is induced. Results *in vitro* and *in vivo* confirm that initially (short-term hypothyroidism) the stem cells are driven to proliferate and expand while later (long-term hypothyroidism) differentiate into thyrotropes.

DOI: 10.1530/endoabs.56.P780

P781

SOM230 exerts anti-proliferative actions by reducing phospho-ERK1/2 levels in ACTH-secreting pituitary tumour cells

Donatella Treppiedi, Erika Peverelli, Elena Giardino, Rosa Catalano, Federica Mangili, Maura Arosio & Giovanna Mantovani
Endocrine Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico; Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.

Currently, the multi-ligand somatostatin (SS) analogue pasireotide (SOM230) is the only pituitary-targeted drug used to treat patients with Cushing's disease. SOM230 displays the highest affinity to somatostatin receptor type 5 (SSTR5) and compared to octreotide resulted more effective in reducing ACTH release. Despite its anti-secretory role, SOM230 has been associated with tumor shrinkage in patients subjected to long term treatment, although to date the key factors

involved are poor elucidated. The present work aimed to investigate the molecular mechanisms implicated in SOM230-induced cytostatic and cytotoxic effects in ACTH-secreting primary tumour cultures and murine corticotroph tumour cells line, AtT-20. First, by western blot we found SSTR5 expressed at comparable levels in 17 different ACTH-secreting pituitary samples, whereas SSTR2 was detectable in 15 out of 17 tissues. SSTR5 and SSTR2 were expressed in AtT-20 cells. Then, we tested the effect of 96h stimulation with 1 μ M SOM230 on cell proliferation in 6 different ACTH-secreting tumors by measuring 5-bromo-20-deoxyuridine incorporation during DNA synthesis. We found a significant *in vitro* suppression of cell growth in half of the analyzed samples ($-12.1 \pm 4.3\%$, $P < 0.01$). Accordingly, SOM230 significantly inhibited cell growth in a dose-dependent manner in AtT-20 cells ($-10.5 \pm 7.7\%$ at 10 nM, $P < 0.05$; $-3.9 \pm 10.9\%$ at 100nM, $P < 0.05$; $-26.8 \pm 8.9\%$ at 1 μ M, $P < 0.01$), whilst octreotide was effective only at 1 μ M ($-13.3 \pm 9.1\%$, $P < 0.05$). To investigate whether direct antiproliferative actions SOM230-mediated might involve MAPK and cyclins pathways, we evaluated the expression level of phospho-ERK1/2 and CD1 in ACTH-secreting primary cultures exposed to 1 μ M of SOM230. SOM230 reduced phospho-ERK1/2 levels in 5 of 8 tumours tested ($-36.4 \pm 20.5\%$, $P < 0.01$), whereas no significant difference was found in CD1 expression levels in 3 tumours. These data were further confirmed in AtT-20 cells, where octreotide did not have any effect. Furthermore, we found that 48h incubation with 1 μ M SOM230 was able to induce a significant increase of caspase 3/7 activity in 2 of 4 ACTH-secreting primary cultures ($17 \pm 3.6\%$, $P < 0.05$). Altogether these data suggest a downstream implication of phospho-ERK1/2 inhibition in ACTH-secreting pituitary tumour cells by SOM230 resulting in cell proliferation suppression and indicating that broader-spectrum SS analogues may play a crucial role in the treatment of tumours where the MAPK pathway is overactivated. Moreover, we describe a pro-apoptotic effect of SOM230. Ongoing experiments are aimed to discriminate the specificity effects played by SSTR5 and SSTR2.

DOI: 10.1530/endoabs.56.P781

P782

Abstract withdrawn.

P783

Corticotroph pituitary adenomas: the functioning vs the silent: a gene expression study comparing differentially expressed genes in the regulation of POMC

Kjersti Ringvoll Normann^{1,2,3}, Arvind Sundaram⁴,
Kristin Astrid Berland Øystese^{1,2}, Tove Lekva³, Alexander Eieland¹,
Jens Bollerslev^{1,2} & Nicoleta Cristina Olarescu^{1,3}

¹Section of Specialized Endocrinology, Department of Endocrinology, Oslo University Hospital, Oslo, Norway; ²Faculty of Medicine, University of Oslo, Oslo, Norway; ³Research Institute for Internal Medicine, Oslo University Hospital, Oslo, Norway; ⁴Department of Medical Genetics, Oslo University Hospital, Oslo, Norway.

Background

The exact mechanism behind the hypersecretion of ACTH and lack of negative cortisol feedback on POMC regulation in functional corticotroph adenomas (FCA) is unknown. Silent corticotroph adenomas (SCA) express, but do not secrete functional ACTH and have lower POMC expression. Using RT-qPCR and immunohistochemistry, previous studies have identified some POMC-transcription factors, regulators and processing enzymes to be differentially expressed